Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis

TORONTO – A highly anticipated phase III trial of an anti-tau drug has posted negative topline results, conferring no cognitive or functional benefits when given in conjunction with standard-of-care...
Source: Clinical Psychiatry News - Category: Psychiatry Source Type: research
More News: Psychiatry